Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: An open-label, prospective study

Rafael Stryjer, Yael Dambinsky, Igor Timinsky, Tamar Green, Moshe Kotler, Abraham Weizman, Baruch Spivak

Research output: Contribution to journalArticlepeer-review

Abstract

The current data suggest that up to 50% of patients with schizophrenia have obsessive-compulsive (OC) symptoms coexisting with psychosis and between 7.8 and 46% of schizophrenia patients also have full-blown obsessive-compulsive disorder (OCD). The aim of this study was to examine the efficacy of the most selective serotonin reuptake inhibitor escitalopram in the management of OCD in schizophrenia patients. The study was an open-label prospective trial of 12 weeks' duration in which escitalopram at a dose of up to 20 mg/day was added to the existing antipsychotic drug regimen in schizophrenia patients with OCD. Fifteen patients (10 men/five women) with the diagnosis of schizophrenia and OCD were recruited for the study (mean age: 39±14, range 21-61 years) and received escitalopram according to the study design. A significant improvement was observed in the total Yale Brown Obsessive-Compulsive Scale (Y-BOCS) scores and in the scores of both the Y-BOCS-Obsession and the Y-BOCS-Compulsion subscale at the end point. In addition, a significant improvement was observed in the total scores of the Positive and Negative Syndrome Scale and particularly in scores of anxiety, tension, depression, and preoccupation items. No adverse effects of escitalopram were reported by patients during the trial. In our prospective 12-week open-label study, escitalopram 20 mg/day was well tolerated and improved OC symptoms in schizophrenia patients. Our preliminary results are encouraging and a double-blind randomized study is required to confirm our results.

Original languageEnglish
Pages (from-to)96-98
Number of pages3
JournalInternational Clinical Psychopharmacology
Volume28
Issue number2
DOIs
StatePublished - Mar 2013

Keywords

  • escitalopram
  • obsessivecompulsive disorder
  • schizophrenia

Fingerprint

Dive into the research topics of 'Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: An open-label, prospective study'. Together they form a unique fingerprint.

Cite this